236 related articles for article (PubMed ID: 20423339)
1. New drugs for neglected infectious diseases: Chagas' disease.
Machado FS; Tanowitz HB; Teixeira MM
Br J Pharmacol; 2010 May; 160(2):258-9. PubMed ID: 20423339
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of Chagas' disease].
Apt W
Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
[No Abstract] [Full Text] [Related]
3. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease.
Guedes PM; Oliveira FS; Gutierrez FR; da Silva GK; Rodrigues GJ; Bendhack LM; Franco DW; Do Valle Matta MA; Zamboni DS; da Silva RS; Silva JS
Br J Pharmacol; 2010 May; 160(2):270-82. PubMed ID: 20128813
[TBL] [Abstract][Full Text] [Related]
5. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
6. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
7. Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease.
Assíria Fontes Martins T; de Figueiredo Diniz L; Mazzeti AL; da Silva do Nascimento ÁF; Caldas S; Caldas IS; de Andrade IM; Ribeiro I; Bahia MT
PLoS One; 2015; 10(6):e0128707. PubMed ID: 26076455
[TBL] [Abstract][Full Text] [Related]
8. Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
Faúndez M; López-Muñoz R; Torres G; Morello A; Ferreira J; Kemmerling U; Orellana M; Maya JD
Antimicrob Agents Chemother; 2008 May; 52(5):1837-9. PubMed ID: 18332173
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
[TBL] [Abstract][Full Text] [Related]
10. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
Cevey ÁC; Mirkin GA; Penas FN; Goren NB
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
[TBL] [Abstract][Full Text] [Related]
11. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
12. [Nifurtimox, a bright future for treatment of Chagas disease].
Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of Chagas' disease: status and new developments.
Cerecetto H; González M
Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
[TBL] [Abstract][Full Text] [Related]
14. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.
Molina I; Perin L; Aviles AS; de Abreu Vieira PM; da Silva Fonseca K; Cunha LM; Carneiro CM
Acta Trop; 2020 Jan; 201():105218. PubMed ID: 31610148
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide associated with benznidazole.
Valdez RH; Tonin LT; Ueda-Nakamura T; Silva SO; Dias Filho BP; Kaneshima EN; Yamada-Ogatta SF; Yamauchi LM; Sarragiotto MH; Nakamura CV
Antimicrob Agents Chemother; 2012 Jan; 56(1):507-12. PubMed ID: 22037851
[TBL] [Abstract][Full Text] [Related]
17. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
Wilkinson SR; Bot C; Kelly JM; Hall BS
Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
[TBL] [Abstract][Full Text] [Related]
18. Drug Discovery for Paediatric Chagas Disease.
Thota S; Morel CM
Mini Rev Med Chem; 2018; 18(9):776-780. PubMed ID: 26202205
[TBL] [Abstract][Full Text] [Related]
19. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
20. First century of Chagas' disease: an overview on novel approaches to nifurtimox and benzonidazole delivery systems.
Salomon CJ
J Pharm Sci; 2012 Mar; 101(3):888-94. PubMed ID: 22161779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]